What You Should Know: - Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in additional funding reaching a total seed round of $12M. - The latest fundraising is led by angel investor Danny Tocatly and existing investor NFX, and will be used to expand US operations, drive commercial partnerships, and scale product offerings. Expanding US Operations and Fostering Commercial
Read More
Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
What You Should Know: - Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know: - Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records. - Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Tavros Therapeutics Raises $7.5M to Develop Targeted Cancer Therapies
What You Should Know: - Tavros Therapeutics, a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities raises $7.5 million in Seed II financing co-led by existing investor Piedmont Capital Investments and new investor KdT Ventures, with participation from Alexandria Venture Investments. - Tavros launched in 2020 with a $3 million seed financing by Piedmont Capital Investments and a strategic collaboration with Zentalis
Read More
Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures
What You Should Know: Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures. Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Syapse and Pierian Partner to Power Precision Oncology
What You Should Know: - Syapse, a real-world evidence company is teaming up with Pierian®, a provider of advanced clinical genomics technology on a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida. - The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant
Read More
HealthQuest Capital Closes $675M for Fund IV to Invest in Transformational Healthcare Companies
What You Should Know: - HealthQuest Capital, a sector specialist capital firm focused on companies optimizing value in healthcare, today announced the close of HealthQuest Partners IV, L.P., at its hard cap of $675M . - The oversubscribed fund will enable HealthQuest to continue to invest in growth-stage companies that are revolutionizing the healthcare industry. Providing Growth Capital to Companies Transforming Healthcare Founded in 2013 by Garheng Kong, a physician, scientist, and
Read More
OncoHost Raises $35M for AI-Powered Precision Oncology Platform
What You Should Know: - OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. Additional investors included leading Israeli financial firm Leumi Partners, Israel’s largest pension fund Menora Mivtachim, OurCrowd and other existing investors. - The funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial as well as support its upcoming
Read More
Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions
What You Should Know: - Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven precision oncology solutions to deliver precision oncology care. - Through this research agreement, VUNO will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for more precise diagnosis, prognosis and treatment stratification in cancer. - This collaborative agreement combines
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
